BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Posted: June 4, 2024 at 2:49 am

BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme (CDP) award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

Link:
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

Related Posts